Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Run a search on a company

Nectar Lifescience Ltd

Pharmaceuticals & Biotechnology | Small Cap

Nectar Lifescience Ltd Health Insights
Health Score : 3.83Health Score : 3.83

Nectar Lifescience Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strengths in solvency and profitability, driven by a solid equity base and returns on capital employed, alongside prudent capital expenditure management. However, it faces challenges in liquidity, growth, and efficiency, which are areas needing attention. The absence of revenue growth and low coverage ratios are significant concerns. While the company maintains a strong equity position, improvements in operational efficiency and revenue generation are crucial for sustained financial health and future prospects.

Latest Report

View All
Quarterly Financial Results Q3 FY 2025-26

Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Overview
Ratio
Financial
Nectar Lifescience Ltd Health Insights
Health Score : 3.83Health Score : 3.83

Nectar Lifescience Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strengths in solvency and profitability, driven by a solid equity base and returns on capital employed, alongside prudent capital expenditure management. However, it faces challenges in liquidity, growth, and efficiency, which are areas needing attention. The absence of revenue growth and low coverage ratios are significant concerns. While the company maintains a strong equity position, improvements in operational efficiency and revenue generation are crucial for sustained financial health and future prospects.

Latest Report

View All
Quarterly Financial Results Q3 FY 2025-26

Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Neutral

Overall Valuation Score

Highly Undervalued
Undervalued
Neutral
Overvalued
Highly Overvalued
Neutral

P/E RATIO (TTM)

-1.69

Highly Undervalued

Industry Median

23.93

Highly Undervalued
Highly Undervalued

Small Cap Median

23.93

Highly Undervalued

P/E RATIO

-2.67

P/B RATIO

0.32

Highly Undervalued

Industry Median

2.53

Highly Undervalued
Highly Undervalued

Small Cap Median

2.53

Highly Undervalued

P/S RATIO

0.18

Highly Undervalued

Industry Median

1.35

Highly Undervalued
Highly Undervalued

Small Cap Median

1.35

Highly Undervalued

Others

Neutral

PEG RATIO

0.00

Neutral
Highly Undervalued

EV/EBITDA RATIO

-13.79

Highly Undervalued

The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹13.56 as on Jun 15, 2026.

Markets Depth NSE

Buy Orders

  1. Bid

    Quantity

    Orders

  2. No buy depth

  3. Total

    0

    0

Sell Orders

  1. Ask

    Quantity

    Orders

  2. No sell depth

  3. Total

    0

    0

BidsOffers
50.00%50.00%

Markets Today NSE

  1. High

    0.00

  2. Low

    0.00

  3. Open

    0.00

  4. Close

    0.00

  5. Prev Close

    0.00

  6. Avg Price

    0.00

  7. Volume

    0

  8. Last Traded Quantity

    0

  9. Last Traded Time

    N/A

Price Movement Indicator

0.00

0.00
Today's Low

0.00
Today's High

Quarterly Report23rd Jan 26

Quarterly Financial Results Q3 FY 2025-26

BEARISH SENTIMENT

Growth Ratio Summary
Growth Ratio SummaryGrowth Score : 2.00

The company's growth ratios are generally poor. The absence of revenue and net income growth, combined with negative growth in operating profit, earnings per share, and assets, indicates significant challenges in expanding its business. This suggests a need for strategic initiatives to stimulate growth and improve financial performance. Current trends pose a risk to future sustainability.

PoorRevenue Growth RatePoor
PoorOperating Profit Growth RatePoor
PoorEarnings Per Share (EPS) GrowthPoor
PoorAsset Growth RatePoor
PoorNet Income Growth RatePoor
Growth RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue Growth Rate8.05-8.7110.66-1.07-99.88
Operating Profit Growth Rate45.87-66.67186.79-119.7496.67
Earnings Per Share (EPS) Growth-134.25-196.43-120.37-2404.55197.44
Asset Growth Rate0.13-8.450.09-6.57-69.61
Net Income Growth Rate-134.25-196-120.83-2380157.02
01.

Revenue Growth Rate

02.

Operating Profit Growth Rate

03.

Earnings Per Share (EPS) Growth

04.

Asset Growth Rate

05.

Net Income Growth Rate

Financial Ratio Summary
Financial Ratio SummaryFinancial Score : 4.00

The company's financial ratios reveal a mixed performance. Capital expenditures are well-managed, but adjusted earnings per share, cash earnings per share, book value per share, and dividend per share are low. This suggests a need for improved earnings generation and shareholder returns. Efficient management of capital expenditures can support future growth, but enhancing overall financial performance is essential.

PoorAdjusted Earnings Per Share (Adjusted EPS)Poor
WeakCash Earnings Per Share (Cash EPS)Weak
PoorBook Value Per SharePoor
PoorDividend Per Share (DPS)Poor
ExcellentCapital Expenditures (CapEx)Excellent
Financial RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Adjusted Earnings Per Share (Adjusted EPS)0.82-2.950.23-5.18-3
Cash Earnings Per Share (Cash EPS)3.731.593-2.36-15.42
Book Value Per Share49.4148.3648.5943.4530.63
Dividend Per Share (DPS)00000
Capital Expenditures (CapEx)155029448
01.

Adjusted Earnings Per Share (Adjusted EPS)

02.

Cash Earnings Per Share (Cash EPS)

03.

Book Value Per Share

04.

Dividend Per Share (DPS)

05.

Capital Expenditures (CapEx)

Profitability Ratio Summary
Profitability Ratio SummaryProfitability Score : 4.00

The company's profitability ratios present a mixed scenario. Returns on capital employed is good, but gross profit, return on equity, return on assets, operating margin, and net margin are low. This suggests limited overall profitability despite efficient capital utilization. Focus on improving margins and asset returns is crucial for enhancing overall profitability.

PoorGross Profit MarginPoor
ExcellentReturn on Capital Employed (ROCE)Excellent
PoorReturn on Equity (ROE)Poor
PoorReturn on Assets (ROA)Poor
PoorOperating MarginPoor
PoorNet MarginPoor
Profitability RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Profit Margin6.13-0.395.41-5.53-2950
Return on Capital Employed (ROCE)506-5-5
Return on Equity (ROE)2.3-2.260.47-11.92-50.34
Return on Assets (ROA)6.652.426.94-1.47-9.49
Operating Margin9.553.499.04-1.8-2950
Net Margin1.5-1.580.3-6.85-14650
01.

Gross Profit Margin

02.

Return on Capital Employed (ROCE)

03.

Return on Equity (ROE)

04.

Return on Assets (ROA)

05.

Operating Margin

06.

Net Margin

Efficiency Ratio Summary
Efficiency Ratio SummaryEfficiency Score : 4.67

The company's efficiency ratios present a mixed picture. While days sales in inventory and receivable days are high, fixed asset, inventory, receivables, and capital turnover ratios are very low. This suggests the company may not be effectively utilizing its assets to generate revenue, but has good sales days in inventory and good receivable days. Overall efficiency could be improved by optimizing asset utilization.

PoorFixed Asset Turnover RatioPoor
PoorInventory Turnover RatioPoor
PoorReceivables Turnover RatioPoor
ExcellentDays Sales in Inventory RatioExcellent
ExcellentReceivable DaysExcellent
PoorCapital Turnover RatioPoor
Efficiency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Fixed Asset Turnover Ratio2.32.32.622.630.02
Inventory Turnover Ratio2.512.292.32.510.18
Receivables Turnover Ratio4.054.185.14.60.01
Days Sales in Inventory Ratio145.42159.39158.7145.422027.78
Receivable Days90.1287.3271.5779.3536500
Capital Turnover Ratio1.211.181.391.640
01.

Fixed Asset Turnover Ratio

02.

Inventory Turnover Ratio

03.

Receivables Turnover Ratio

04.

Days Sales in Inventory Ratio

05.

Receivable Days

06.

Capital Turnover Ratio

Coverage Ratio Summary
Coverage Ratio SummaryCoverage Score : 2.00

The coverage ratios are low, reflecting potential difficulties in meeting interest and dividend obligations. The interest coverage ratio, being close to the threshold, suggests a limited cushion for debt servicing. The equity dividend coverage ratio further confirms these challenges, highlighting the need for improved earnings and cash flow to comfortably cover these obligations.

PoorInterest Coverage RatioPoor
PoorEquity Dividend Coverage RatioPoor
Coverage RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Interest Coverage Ratio1.430.471.21-1.16-7.97
Equity Dividend Coverage Ratio
01.

Interest Coverage Ratio

02.

Equity Dividend Coverage Ratio

Solvency Ratio Summary
Solvency Ratio SummarySolvency Score : 9.00

The company's solvency position is strong. The absence of debt paired with a reasonably good equity ratio suggests financial stability and low risk of financial distress. This indicates a conservative approach to financing, which can be beneficial in volatile economic conditions. However, the company should ensure that this approach does not limit growth opportunities.

ExcellentDebt RatioExcellent
ExcellentDebt to Equity RatioExcellent
AverageEquity RatioAverage
ExcellentDebt To Asset RatioExcellent
Solvency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debt Ratio0.210.180.120.060
Debt to Equity Ratio0.270.220.140.060
Equity Ratio0.790.820.880.941
Debt To Asset Ratio0.120.10.060.030
01.

Debt Ratio

02.

Debt to Equity Ratio

03.

Equity Ratio

04.

Debt To Asset Ratio

Liquidity Ratio Summary
Liquidity Ratio SummaryLiquidity Score : 2.00

The company's liquidity position is weak. Low current, quick, and cash ratios indicate potential difficulties in meeting short-term obligations. The operating cash flow ratio further confirms these challenges, highlighting the need for improved working capital management to ensure smooth operational activities. This situation requires careful monitoring to avoid potential financial distress.

PoorCurrent RatioPoor
PoorQuick RatioPoor
PoorCash RatioPoor
PoorOperating Cash Flow RatioPoor
Liquidity RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Current Ratio1.561.611.511.3212.92
Quick Ratio0.910.860.790.6512.92
Cash Ratio0.020.020.020.022.87
Operating Cash Flow Ratio0.090.150.230.16-8.95
01.

Current Ratio

02.

Quick Ratio

03.

Cash Ratio

04.

Operating Cash Flow Ratio

Peer Comparison With 12 Companies

Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.

NO Company Name Health Score P/E Ratio Valuation OPM EPS Latest Profit & Loss
1Medico Remedies Ltd6.6137.70Overvalued17.001.5813.00
2Kilitch Drugs (India) Ltd6.6121.54Neutral37.009.2730.00
3SMS Lifesciences India Ltd6.5921.20Undervalued45.0070.6819.00
4Infinium Pharmachem Ltd6.4226.90Neutral22.006.4314.00
5Medicamen Biotech Ltd5.7332.19Neutral20.006.9410.00
6Aarey Drugs & Pharmaceuticals Ltd5.7359.71Neutral7.001.404.00
7Albert David Ltd5.63-272.47Neutral5.00-2.62-1.00
8BPL Ltd5.46-31.11Neutral-4.82-3.00-8.55
9Zim Laboratories Ltd5.4141.96Neutral30.001.116.00
10Lyka Labs Ltd4.77-23.98Neutral-4.00-9.05-10.00
11Nectar Lifescience Ltd3.83-2.67Neutral-59.00-2.95-293.00
Management Assessment Summary
OrangeBalanced Management

Nectar Lifescience Ltd's management effectiveness presents a mixed assessment. Strengths include sales growth and recent profit growth. However, concerns exist regarding Return on Equity (ROE), and promoter holding. The management's effectiveness is rated as mixed, reflecting both opportunities and challenges.

Category Metric Value Assessment
PROS Sales Growth 3% (3Y) Revenue expansion is evident.
Compounded Profit Growth 28% (3Y) Profit growth is recently strong.
CONS Return on Equity (ROE) 0.47% Shareholder funds yielding poor returns.
Promoter Holding 44.53% (Mar 2025) Decrease in promoter holding.
AverageFinancial Performance & GrowthAverage
WeakCapital Efficiency & ReturnsWeak
AverageFinancial Health & PrudenceAverage
AverageShareholding & Ownership StructureAverage
01.

Financial Performance & Growth

02.

Capital Efficiency & Returns

03.

Financial Health & Prudence

04.

Shareholding & Ownership Structure

Risk Assessment Summary
OrangeBalanced Risk

Nectar Lifescience Ltd faces a moderate risk profile due to segment performance volatility. The overall risk is assessed as moderate due to fluctuations in quarterly sales and profits.

AverageSegment performance volatilityAverage
AverageForeign exchange or interest rate exposureAverage
01.

Segment performance volatility

02.

Foreign exchange or interest rate exposure

0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe